Liquid formulation of ifosfamide increased risk of encephalopathy: A case-control study in a pediatric population

ANSM, 2016 Gaudin, 2016 Chambord, 2019, Ifosfamide-induced encephalopathy: Brand-name (Holoxan®) vs generic formulation (Ifosfamide EG®), J Clin Pharm Ther, 44, 372, 10.1111/jcpt.12823 Miremont Salamé, 2016, Causality assessment in pharmacovigilance: the French method and its successive updates, Therapie, 71, 179, 10.1016/j.therap.2016.02.010 Highley, 2015, The neurotoxicity and pharmacokinetics of oral ifosfamide, J Anal Oncol, 4, 13, 10.6000/1927-7229.2015.04.01.3 Sauerbier, 1990 Mirejovsky, 2005 Daftary, 2007 Van Dyk, 1972, Unexpected toxicity in patients treated with iphosphamide, Cancer Res, 32, 921 Manegold, 1992, Oral ifosfamide-mesna: a clinical investigation in advanced non-small-cell lung cancer, Ann Oncol, 3, 723, 10.1093/oxfordjournals.annonc.a058327 Cerny, 1992, The enigma of ifosfamide encephalopathy, Ann Oncol, 3, 679, 10.1093/oxfordjournals.annonc.a058317 Goren, 1986, Dechloroethylation of ifosfamide and neurotoxicity, Lancet, 2, 1219, 10.1016/S0140-6736(86)92227-0 Kaijser, 1996, Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide, in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide, Anticancer Res, 16, 3247 Visarius, 1998, Thiodiglycolic acid is excreted by humans receiving ifosfamide and inhibits mitochondrial function in rats, Drug Metab Dispos, 26, 193 Chatton, 2001, Insights into the mechanisms of ifosfamide encephalopathy: drug metabolites have agonistic effects on alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainite receptors and induce cellular acidification in mouse cortical neurons, J Pharmacol Exp Ther, 299, 1161 Küpfer, 1996, Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy, Eur J Clin Pharmacol, 50, 249, 10.1007/s002280050102 Küpfer, 1994, Prophylaxis and reversal of ifosfamide encephalopathy with methylene blue, Lancet, 343, 763, 10.1016/S0140-6736(94)91839-2 Zhang, 2005, Metabolism and transport of oxazaphosphorines and the clinical implications, Drug Metab Rev, 37, 611, 10.1080/03602530500364023 Kaijser, 1998, Pharmacokinetics of ifosfamide and some metabolites in children, Anticancer Res, 18, 1941 Yule, 1997, Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children, Clin Cancer Res, 3, 1985 Kerbusch, 2001, Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites, Clin Pharmacokinet, 40, 41, 10.2165/00003088-200140010-00004 Kerbusch, 2001, Distribution of ifosfamide and metabolites between plasma and erythrocytes, Biopharm Drug Disp, 22, 99, 10.1002/bdd.257 Howell, 2008, Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant, J Oncol Pharm Pract, 14, 157, 10.1177/1078155208093930 Hansen, 2010, Aprepitant-associated ifosfamide neurotoxicity, J Oncol Pharm Pract, 16, 137 Chenaf, 2017, Incidence of encephalopathy and associeted risk factors in two different ifosfamide formulations, a retrospective bicentric study. 21st Annual Meeting of French Society of Pharmacology and Therapeutics, 19–21 April 2017, Rouen, France, Fundam Clin Pharmacol, 31, 1 Dushenkov, 2017, Drug interactions with aprepitant and fosaprepitant: review of literature and implications for clinical practice, J Oncol Pharm Pract, 23, 296, 10.1177/1078155216631408 Patel, 2017, Aprepitant and fosaprepitant drug interactions: a systematic review, Br J Clin Pharmacol, 83, 2148, 10.1111/bcp.13322 Tajino, 2010, Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity, and risk factors, J Orthop Sci, 15, 104, 10.1007/s00776-009-1431-y Szabatura, 2015, An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center, J Oncol Pharm Pract, 21, 188, 10.1177/1078155214527143